NFE2L2 and myelodysplastic syndrome: The combination of DAC + ATRA decreased the viability of MDS cells, delayed the progression of tumor cells, and prolonged the survival time of mice, and ATRA increased the efficacy of DAC by blocking Nrf2 activation through activation of the RARα-Nrf2 complex, which led to ROS accumulation and ROS-dependent cytotoxicity (Wang et al., 2023).